Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.53 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 14.8× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 64 Days on average.
| TVTX | VCIT | |
|---|---|---|
Market Cap | $4.88B | $72.20B |
Volume | 1,668,577 | 9,562,318 |
Sector | Health | Fixed Income |
52-Week High | $67.52 | $84.82 |
52-Week Low | $26.79 | $77.98 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VCIT trades at $78.48, down slightly by 0.03% with a bullish technical signal supported by oscillators despite bearish moving averages. The ETF maintains consistent dividend payments of $0.34 per share and shows strong institutional interest with recent purchases by Engineers Gate Manager LP and HB Wealth Management. Technical analysis indicates key support at $78 and resistance at $80.
VCIT offers a compelling risk-return profile with a 4.8% yield and 5.1% yield to maturity, benefiting from low 0.03% expense ratio. Risks include interest rate sensitivity and corporate credit exposure, but the fund's intermediate-term corporate bond focus provides balanced income generation for investors seeking steady returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
